Navigation Links
WuXi PharmaTech Receives Award from BASF
Date:7/1/2009

SHANGHAI, July 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had received an award from BASF for excellent service and outstanding contributions in the area of custom synthesis for new crop-protection active ingredients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"We had been looking for a good CRO collaboration partner for years, and today I think we have found one, a top-notch partner," Dr. Alfred Hackenberger, President of the Specialty Chemicals Research Division at BASF, commented at the award ceremony. "And I know that WuXi will continue to provide the same excellent service in the future."

"We are pleased to receive this award by BASF in recognition of the efforts of WuXi's talented team," commented Dr. Ge Li, Chairman and CEO of WuXi AppTec. "We will continue to focus on customer service to earn the trust and support of our partners."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
(Date:7/27/2015)... 27, 2015  Amgen (NASDAQ: AMGN ) today ... results on Thursday, July 30, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
(Date:7/27/2015)... ... , ... Production of high tenacity filament yarn of viscose rayon (excluding sewing ... instance, it surpassed the EUR 106 million mark (in value terms) in 2013, while ... major producer, while Italy is a key consumer. , The high tenacity filament ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... , , , , For purification of endotoxin-free ultrapure , ... Features and benefits , , Less ... DNA , Greater than 90% recovery of plasmid DNA , ... , , , ...
... , , , A crucial step ... To improve the critical steps in the target-labeling process, , ... for use with Affymetrix GeneChip expression arrays. The GeneChip ... of an ongoing collaboration between , QIAGEN and ...
... , , , , , , ... specific and sensitive multiplex PCR without the need for time-consuming , optimization ... , , ... ready-to-use master mix , High specificity ...
Cached Biology Technology:EndoFree Plasmid Kits 2EndoFree Plasmid Kits 3EndoFree Plasmid Kits 4GeneChip Sample Cleanup Module for cleanup of cDNA and in vitro , transcribed cRNA 2QIAGEN Multiplex PCR Kit 2QIAGEN Multiplex PCR Kit 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... than 70 researchers across the globe has uncovered nine ... lead to learning disabilities. The international team studied almost ... disabilities - the largest screen of this type ever ... approximately 1𔃀% of X chromosome genes, when knocked-out, have ...
... for places that can soak up carbon dioxide from the ... gas include the oceans and the enormous trees of tropical ... research now suggests they can store more carbon than previously ... and present-day datasets, Jeanine Rhemtulla of McGill University and David ...
... Five-hundred years ago, Ponce de Leon combed the swamps of ... the 2009 ASBMB Annual Meeting in New Orleans (held in ... exciting talks centering on the new molecular "fountain of youth," ... of longevity may still be a long time away, the ...
Cached Biology News:The genetic X-factor 2The genetic X-factor 3Study reveals potential to amass more carbon in eastern North American forests 2Study reveals potential to amass more carbon in eastern North American forests 3ASBMB Annual Meeting to feature talks on the biochemistry of aging 2ASBMB Annual Meeting to feature talks on the biochemistry of aging 3
...
Agarose, Biotechnology grade, 500g...
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
...
Biology Products: